Show simple item record

dc.creatorPinto, Dora
dc.creatorPark, Young Jun
dc.creatorBeltramello, Martina
dc.creatorWalls, Alexandra C.
dc.creatorTortorici, M. Alejandra
dc.creatorBianchi, Siro
dc.creatorJaconi, Stefano
dc.creatorCulap, Katja
dc.creatorZatta, Fabrizia
dc.creatorDe Marco, Anna
dc.creatorPeter, Alessia
dc.creatorGuarino, Barbara
dc.creatorSpreafico, Roberto
dc.creatorCameroni, Elisabetta
dc.creatorCase, James Brett
dc.creatorChen, Rita E.
dc.creatorHavenar-Daughton, Colin
dc.creatorSnell, Gyorgy
dc.creatorTelenti, Amalio
dc.creatorVirgin, Herbert W.
dc.creatorLanzavecchia, Antonio
dc.creatorDiamond, Michael S.
dc.creatorFink, Katja
dc.creatorVeesler, David
dc.creatorCorti, Davide
dc.date.accessioned2020-07-21T14:41:35Z
dc.date.available2020-07-21T14:41:35Z
dc.date.created2020-05-18
dc.identifier.issn1476-4687spa
dc.identifier.otherhttps://www.nature.com/articles/s41586-020-2349-yspa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/10845
dc.format.extent22 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.publisherScience Directeng
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectAnticuerposspa
dc.titleCross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibodyspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.identifier.doihttps://doi.org/10.1038/s41586-020-2349-yspa
dc.description.abstractenglishSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 20201,2. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease.spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record